Abstract: The invention discloses human secreted polypeptides that circulate at a decreased level in the plasma of patients with cardiovascular disorders. The invention also provides methods of using compositions including the polypeptides, polynucleotides encoding them, and antibodies specific for these polypeptides, for diagnosis, prognosis, and for drug development.

Abstract: The invention discloses human secreted polypeptides that circulate at an increased level in the plasma of patients with cardiovascular disorders. The invention also provides methods of using compositions including the polypeptides, polynucleotides encoding them, and antibodies specific for these polypeptides, for diagnosis, prognosis, and for drug development.

Abstract: The invention discloses human secreted polypeptides that circulate at an increased level in the plasma of patients with cardiovascular disorders. The invention also provides methods of using compositions including the polypeptides, polynucleotides encoding them, and antibodies specific for these polypeptides, for diagnosis, prognosis, and treatment of cardiovascular disorders.

Abstract: Putative Adrenomedullin Receptor polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing Putative Adrenomedullin Receptor polypeptides and polynucleotides in the design of protocols for the treatment of infections such as bacterial, fungal protozoan and viral infections, particularly infections caused by HIV-1 or HIV-2; pain; cancers; diabetes, obesity; anorexia; bulimia; asthma; Parkinson's disease; acute heart failure; hypotension; hypertension, urinary retention, osteoporosis; angina pectoris; myocardial infarction, ulcers; asthma; allergies; benign prostatic hypertrophy; psychotic and neurological disorders, including anxiety, schizophrenia, manic depression, delirium, dementia, severe mental retardation and dyskinesias, such as Huntington's disease or Gilles dela Tourett's syndrome; and pre-eclampsia, among others and diagnostic assays for such conditions.

Abstract: Peptides of the formulaR.sub.1 --HX.sub.1 DX.sub.2 IX.sub.3 Iwherein R.sub.1, X.sub.1, X.sub.2 and X.sub.3 are defined as in the specification having antihypertensive activity without vascoconstricting activity.

Abstract: New peptidic derivatives having the general formula (I): X.sub.1 X.sub.2 X.sub.3 Ile X.sub.5 X.sub.6 wherein X.sub.1 is hydrogen, a rest of histidin, of acetyl-histidin or of D-histidin, X.sub.2 is a rest of alanin, of leucin, of tryptophan, of phenylalanin as well as their homologs in D series, X.sub.3 is a rest of alanin as well as its D series homolog, X.sub.5 is a rest of isoleucin, of alanin, of valin, of norleucin, of leucin and of aspanic acid as well as their D series homologs, X.sub.6 is a rest of tryptophan, of leucin, of isoleucin, of norleucin and their D series homologs, method for the preparation and application of such new derivatives as medicaments.

Abstract: A peptide derivative having the formula: ##STR1## wherein X.sub.1 is hydrogen or cysteine residue,X.sub.3 is a cysteine or alanine residue,X.sub.4 is a residue of asparagine, phenylalanine, leucine, isoleucine, alanine, valine, glycine and their homologues in the D series,X.sub.6 is a residue of tryptophan, phenylalanine, leucine, isoleucine, alanine, valine, glycine, serine, lysine, aspartic acid, tyrosine, threonine and their homologues in the D series,X.sub.9 and X.sub.17 are a residue of glutamic acid, aspartic acid, lysine, arginine, tyrosine, leucine and their homologues in the D series,X.sub.11 is a cysteine or alanine residue,X.sub.14 is a residue of tyrosine, phenylalanine, leucine, isoleucine, alanine, valine, glycine, serine, lysine, aspartic acid, threonine and their homologues in the D series,X.sub.21 is hydrogen or a tryptophan or D-tryptophan residue, and the derivatives possessing, where appropriate, one or two disulfide bridges, with the proviso that X.sub.